Pardis Zarifkar|Archith Kamath|C. Robinson|Nelli Morgulchik|Surbhi Shah|Mark T. K. Cheng|Catherine Dominic|AbdulBasit Fehintola|Gaurav Bhalla|Tharanika Ahillan|Laure Mourgue d’Algue|J. Lee|Anuj Pareek|Matthew Carey|D.J. Hughes|Mary Miller|Victoria K. Woodcock|Madhumita Shrotri
Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: a Systematic Review and Meta-analysis
Aarhus University Hospital|John Radcliffe Hospital|University of Oxford|John Radcliffe Hospital|University of Oxford|Imperial College London|University of Cambridge|University of Cambridge|Queen Mary University of London|University of Ibadan|Queen Mary University of London|University College London|University College London|Faculty (United Kingdom)|University of Oxford|Stanford University|Sobell House|Churchill Hospital|University of Oxford|King's College London|Sobell House|Churchill Hospital|University of Oxford|Churchill Hospital|Oxford University Hospitals NHS Trust|London School of Hygiene & Tropical Medicine
much routine cancer care disrupted due perceived susceptibility sarscov2 infection cancer patients systematically review current evidence base pertaining prevalence presentation outcome covid19 cancer patients order inform policy practice going forwards keywordstructured systematic search conducted pubmed cochrane embase medrxiv databases studies reporting primary data covid19 cancer patients studies critically appraised using nih national heart lung blood institutes quality assessment tool set pooled prevalence cancer comorbidity patients covid19 pooled inhospital mortality risk covid19 cancer patients derived randomeffects metaanalyses total 110 studies 10 countries included pooled prevalence cancer comorbidity hospitalised patients covid19 26 95 confidence interval 18 35 i2 920 specifically 17 95 confidence interval 13 23 i2 576 china 56 95 confidence interval 45 67 i2 823 western countries patients commonly presented nonspecific symptoms fever dyspnoea chest tightness addition decreased arterial oxygen saturation ground glass opacities computer tomography nonspecific changes inflammatory markers pooled inhospital mortality risk among patients covid19 cancer 141 95 confidence interval 91 198 i2 523 identified impeding questions need answered provide foundation iterative review developing evidence base inform policy practice going forwards analyses available data corroborate unfavourable outcome hospitalised patients covid19 cancer findings encourage future studies report detailed social demographic clinical characteristics cancer patients including performance status primary cancer type stage well history anticancer therapeutic interventions